A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy (MM17)

Dataset includes: Data for 50 patients with newly diagnosed, transplant eligible, multiple myeloma using carfilzomib-thalidomide-dexamethasone (CarTD), in a randomised trial Demographic data, diagnostic data, treatment data, outcome data

本数据集涵盖一项随机试验中，50例新诊断且符合移植条件的多发性骨髓瘤（multiple myeloma）患者的相关数据，这些患者均接受卡非佐米-沙利度胺-地塞米松（CarTD）方案治疗。数据集包含人口统计学数据、诊断数据、治疗数据及结局数据。